Race a factor in receiving transplant treatment for bone marrow cancer but does not affect outcomes

Dec 08, 2008

A new study by researchers at The Medical College of Wisconsin Cancer Center Milwaukee, has found that African Americans and whites have identical survival rates after undergoing autologous (self donor) bone marrow transplant treatment for a common cancer of the bone marrow (multiple myeloma). However, in a previous study the researchers showed that African Americans were only half as likely as whites to actually receive a bone marrow transplant, the well-established life-prolonging treatment for the disease.

The results of their study were presented today (Dec. 8) at the 50th Annual meeting of the American Society of Hematology in San Francisco by lead researcher, Parameswaran Hari, M.D., assistant professor of medicine in neoplastic diseases. Dr. Hari who practices at Froedtert Hospital, a major teaching affiliate of the College.

Over 15,000 Americans are diagnosed with multiple myeloma each year. The incidence of multiple myeloma in African Americans is twice that of whites and African Americans are twice as likely to die from this disease. It is also the most common diagnosis for which bone a marrow transplant, also known as hematopoietic stem cell transplant, is performed.

Dr. Hari and a research team from the Center for International Blood and Marrow Transplant Research (CIBMTR) compared the estimated rate of transplants and incidence rate of myeloma from SEER data (Surveillance Epidemiology and End Results, a program of the National Cancer Institute). They concluded that African Americans are less likely to undergo transplants.

Further, a review of data reported to the CIBMTR showed no significant difference between the races in survival, progression–free survival, non-relapse mortality or relapse after transplantation. (CIBMTR, headquartered at the Medical College, is the world's largest clinical database of related blood and marrow transplants with the goal of increasing scientific knowledge of blood and marrow transplantation through research).

"This suggests that equal treatment results in equal outcomes," says Dr. Hari. "More study is needed to correct the causes of this imbalance in transplant rates especially since the transplant treatment itself is equally efficacious but less likely to be applied in African Americans. We need to now find out more about the patients who are being excluded from this procedure and why.

"African Americans also received transplants later in the course of their disease, on average, more than a year after diagnosis." says Dr. Hari.

The researchers also found that African Americans receiving autologous transplants were generally younger, and more likely to be both female and to have other illnesses such as obesity, diabetes and high blood pressure, compared to their white counterparts. "However, the outcomes were very similar, in terms of survival, survival without disease progression, relapse of myeloma and treatment-related mortality.

Dr. Hari believes that these subtle differences between patient groups at baseline may hold clues to why African Americans are less likely to get to transplantation.

Source: Medical College of Wisconsin

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Up in arms

Jan 28, 2014

In December 2012, when Adam Lanza stormed into the Sandy Hook Elementary School in Newtown, Conn., with a rifle and killed 20 children and six adult staff members, the United States found itself immersed ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.